119 E. Union St., Suite B
Pasadena, CA 91103
+1 (213) 785-8073 Phone
(213) 995-5010 Fax
Loyola Law School, Los Angeles, J.D.
University of California, Los Angeles, BS, Chemistry
Dan Kimbell is AV rated, has been a patent and trademark prosecution and licensing attorney for over 23 years, and has prosecuted and secured well over 1,000 patents and 1,000 trademarks in a wide variety of technical and business areas. In 2013 he earned the prestigious Certified Licensing Professional® (CLP) credential. The CLP credential acknowledges licensing professionals who have demonstrated the highest experience and proficiency in licensing and the commercialization of intellectual property and is built on internationally applicable standards of practice, knowledge, and ethics.
Dan is particularly skilled in handling and advising companies on how to best leverage IP to improve business.
Most patent attorneys have never personally started a technology company and do not fully appreciate the challenges faced by high tech entrepreneurs. Dan has co-founded three startup companies. His latest is Emmaus Medical, Inc. (www.emmausmedical.com), a pharmaceutical company which he co-founded in 2000 and ran as its COO for 10 years. In December, 2014, the company completed its Phase III clinical trial for a treatment for sickle cell disease using L-glutamine. This Phase III clinical trial evaluated the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia. This trial met both the primary and secondary endpoints of the clinical trial (reduction in the median frequency of sickle cell crises and reduction in the median frequency of hospitalizations). The treatment also demonstrated a well-tolerated safety profile. A New Drug Application (NDA) is planned for submission to the FDA in mid-2016 for marketing approval of this treatment, which if approved, will achieve the goal of bringing this treatment to millions around the world suffering from this devastating genetic disease.